ABOUT US

John Gregg, MBA

President & CEO

Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting microbiome companies for investors. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). 

John established his reputation in senior marketing and new product planning roles at leading large drug companies including Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. John successfully launched Symbiomix Therapeutics, LLC, and LifeQual Pharmaceuticals, Inc., where he was the founding CEO.  John was also Executive Director of Commercial Operations for AkaRx, an oncology spinout of Astellas Pharma.

John holds a B.A. degree in biology (microbiology focus) from the University of Chicago and an M.B.A. in Marketing and International Business from the Leonard Stern School of Business at New York University. 

Paul Jeffreys, MBA

Paul began his career as an organic chemist at Schering, then Merck. After several years he joined Pfizer in US Marketing. For nearly 30 years where his last position was VP, Early Commercial Development, he was responsible for Pfizer’s Primary Care Division pipeline products and business development deals.

 

Over the years Paul contributed to Pfizer’s new product commercialization, business development, and global marketing across many therapeutic areas including infectious disease, allergy, respiratory, neuroscience, and pain. As well as many of Pfizer’s successful licensing and acquisition deals. Later in his career, he led Pfizer’s cardiovascular franchise, including new product and global marketing. Many of Paul’s products became billion-dollar sellers including Zyrtec, Aricept, Diflucan, Chantix, Geodon, Norvasc, and Lipitor. Just before leaving Pfizer Paul was co-leader on Eliquis, now one of Pfizer’s most successful products, selling over $5 billion/year with partner BMS. 

 

Paul now uses his pharmaceutical development and deal-making experience to help biotechs maximize their product or company value to potential investors or pharma partners.

He aided Excaliard in achieving acquisition by Pfizer. He has consulted for Aralez, Oligomerix, Saniona, and MAPS Public Benefit Corp. As a partner in BusStim, he is an advisor to Shifa Biomedical and 4 other biotechs. He is on the Board of Directors for Arkay Therapeutics.

Dr. Steve Bartle

Dr. Bartle has a M.S., Ph.D., and postdoctoral experience in Ruminant Nutrition, with an emphasis on beef cattle nutrition and management. Dr. Bartle spent 10 years as a research scientist at Texas Tech University working primarily with feedlot cattle.  He then spent 18 years in the feed industry, primarily as a Research Manager for a major feed company, but also in technical service and division management.  Dr. Bartle then accepted an opportunity to return to a university setting with a position as Director of Research for the Beef Cattle Institute at Kansas State University.  Dr. Bartle retired from this position in 2016.  He credits his passion for animal nutrition with having grown up on a farm in North Dakota.

Bruce Nemlich, MBA

Bruce has worked across a wide range of pharmaceutical commercial strategy, analysis, and implementation over the past 30 years at Pfizer, McKinsey, and in his own consulting practice.  At Pfizer, he led the Management Science Group and the Resource Allocation Group where besides supporting sales and marketing optimization, he worked with Business Development and Commercial Development developing potential product strategy and stress-testing forecasts.

 

Bruce played key roles on various co-promotion deals including Lipitor, Celebrex, Spiriva, and Eliquis, especially negotiating promotion resource levels.  His insights gave Pfizer the confidence to pursue the co-promotion deal with Warner-Lambert for atorvastatin.  He supported the initial and on-going co-promotion negotiations of what eventually became Lipitor. 

 

On Spiriva, Bruce created the US Sales Capabilities Presentation to initiate the deal, negotiated ongoing promotion levels and standards, and later consulted to Boehringer-Ingelheim on a peri-LOE strategy for Spiriva and re-launch of Stiolto, leveraging their new respiratory delivery device.

Bruce holds an MBA from the University of Chicago in Marketing, Econometrics, and Finance, and Bachelor of Science in Transportation, Urban Planning, and Behavioral Science from the Massachusetts Institute of Technology.

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team anticipated the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

CEO John Gregg has over 35 years in the pharmaceutical industry and his past start-ups have successfully brought new anti-infective drugs to market.  John is uniquely qualified as he was previously responsible for new product planning for Pfizer for its picorna virus/rhino virus/coronavirus R&D program.